Back to Newsroom

Endocyte Regains Worldwide Rights to Vintafolide

WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) — Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide.

Click here to read more